文献速递神经核医学

[18F]Florzolotau PET 用于疑似 4 重复 Tau 蛋白病患者帕金森综合征的鉴别诊断

[18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies.
PubMed 文献 · J Nucl Med · 2025-06-02

本研究回顾性分析 94 例连续入组的帕金森综合征且可能为 4R tau 蛋白病患者的 [18F]florzolotau PET 视觉判读,以 interdisciplinary 共识诊断为参考标准。结果显示 4R 样结合模式在 PSP/CBD 组的出现率(84.3%)显著高于其他组(11.6%,P<0.0001),ROC 曲线下面积(AUC)为 0.87(灵敏度 84.3%,特异度 88.4%)。作者认为 [18F]florzolotau PET 是鉴别神经退行性帕金森综合征的有前景的生物标志物。

要点

  • 在真实世界帕金森综合征队列中,[18F]florzolotau PET 视觉判读 4R 样模式鉴别 PSP/CBD 的 AUC 为 0.87。
  • 4R 样模式在共识诊断为 PSP/CBD 的患者中占 84.3%,在其他组中占 11.6%(P<0.0001)。
  • AD 样模式见于全部共识诊断为 AD 的患者(100%),其他组出现频率高但幅度较低(67.4%,P<0.01)。

核心结论

  • 基于真实世界帕金森综合征患者人群,通过预先定义的 4R 样结合模式对 [18F]florzolotau PET 进行简单视觉评估,可高准确度识别共识诊断为 PSP/CBD 的患者。
  • [18F]florzolotau PET 是鉴别神经退行性帕金森综合征的有前景的生物标志物。

研究设计与样本

  • 回顾性分析 94 例连续入组的帕金森综合征且可能为 4R tau 蛋白病、为鉴别诊断接受 [18F]florzolotau PET 的患者。
  • 以基于全面临床和影像数据(尤其是 [18F]FDG PET)的 interdisciplinary 共识诊断为参考标准。
  • [18F]florzolotau PET 采用预先定义的 4R 样和阿尔茨海默病(AD)样结合模式进行视觉评估(4 分制),并对 4R 样病例的皮层-皮层下梯度进行评分。
  • 诊断效能通过受试者工作特征(ROC)分析评估。

主要发现

  • 4R 样模式在共识诊断为 PSP/CBD(临床很可能 4R tau 蛋白病的联合诊断组)的患者中更普遍且表达更强(84.3%,平均评分 2.0±1.1),高于所有其他组(11.6%,0.26±0.75,P<0.0001)。
  • AD 样模式见于全部共识诊断为 AD 的患者(100%,2.5±0.9),在所有其他患者组中频率高但幅度较低(67.4%,1.2±1.1,P<0.01)。
  • 4R 样模式鉴别 PSP/CBD 与其他所有患者的 ROC 分析得出曲线下面积(AUC)为 0.87(灵敏度 84.3%,特异度 88.4%)。
  • 同时考虑 AD 样模式(AUC 0.88;logistic 回归,因子 AD 样模式;P=0.53)或排除所有 AD 病例(AUC 0.86)时,[18F]florzolotau PET 的诊断效能未改变。
  • 4R 样结合患者中皮质基底节综合征的存在与优先皮层结合强烈相关(AUC 0.89)。

关键数值与推荐

  • 4R 样模式在 PSP/CBD 组的发生率为 84.3%(平均评分 2.0±1.1),其他组为 11.6%(0.26±0.75),P<0.0001。
  • AD 样模式在 AD 组的发生率为 100%(2.5±0.9),其他组为 67.4%(1.2±1.1),P<0.01。
  • 4R 样模式鉴别 PSP/CBD 的 AUC 为 0.87(灵敏度 84.3%,特异度 88.4%)。
  • 加入 AD 样模式后 AUC 为 0.88(P=0.53),排除 AD 病例后 AUC 为 0.86。
  • 4R 样结合患者中皮质基底节综合征与优先皮层结合的 AUC 为 0.89。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The second-generation tau radioligand [18F]florzolotau is a promising biomarker for 4-repeat (4R) tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), which are difficult to disentangle clinically. Prior studies evaluating the diagnostic accuracy of [18F]florzolotau PET focused on highly selected patient populations (e.g., PSP-Richardson syndrome or amyloid-β-negative corticobasal syndrome). The present study assesses the diagnostic performance of [18F]florzolotau PET in conjunction with visual reads in a real-world clinical cohort. Methods: Ninety-four consecutive patients with parkinsonism and possible 4R tauopathy undergoing [18F]florzolotau PET for differential diagnosis were enrolled and retrospectively analyzed. The interdisciplinary consensus diagnosis based on comprehensive clinical and imaging data (most notably, [18F]FDG PET) served as the reference standard. [18F]florzolotau PET was assessed visually using predefined 4R-like and Alzheimer disease (AD)-like binding patterns (on a 4-point scale). In addition, 4R-like cases were rated with respect to the cortical-subcortical gradient of 4R-like binding. The diagnostic performance was assessed by receiver operating characteristic (ROC) analyses. Results: The 4R-like pattern was more prevalent and more strongly expressed (84.3%, mean score, 2.0 ± 1.1) in patients with a consensus diagnosis of PSP/CBD (joint diagnostic group of clinically likely 4R tauopathies) than in all other groups (11.6%, 0.26 ± 0.75, P < 0.0001). An AD-like pattern was present in all patients with a consensus diagnosis of AD (100%, 2.5 ± 0.9) and at high frequency, albeit with lower magnitude, in all other patient groups (67.4%, 1.2 ± 1.1, P < 0.01). ROC analysis for the 4R-like pattern (PSP/CBD vs. all other patients) yielded an area under the ROC curve (AUC) of 0.87 (sensitivity, 84.3%; specificity, 88.4%). The diagnostic performance of [18F]florzolotau PET did not change when also considering the AD-like pattern (AUC, 0.88; logistic regression, factor AD-like pattern; P = 0.53) or excluding all cases with AD (AUC, 0.86). The presence of corticobasal syndrome in patients with 4R-like binding was strongly associated with preferentially cortical binding (AUC, 0.89). Conclusion: Based on a real-world population of patients with parkinsonism, we demonstrate that simple visual evaluation of [18F]florzolotau PET by an a priori-defined 4R-like binding pattern allows highly accurate identification of patients with a consensus diagnosis of PSP/CBD. Thus, [18F]florzolotau PET is a promising biomarker for differential diagnosis of neurodegenerative parkinsonian syndromes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Brumberg J, Schröter N, Blazhenets G, et al. [18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies. J Nucl Med. 2025. PMID: 40246540. doi:10.2967/jnumed.124.268956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。